title: Nitric oxide-induced inhibition of aortic smooth muscle cell motility: role of PTP-PEST and adaptor proteins p130cas and Crk.
abstract: Vascular injury increases nitric oxide (NO) levels, and this effect may play a counterregulatory role in neointima formation, by decreasing vascular smooth muscle cell motility. However, the mechanisms underlying this effect are not well established. We tested the hypothesis that NO decreases cell motility by increasing the activity of a protein tyrosine phosphatase (PTP), PTP-PEST, in cultured rat aortic smooth muscle cells. Two NO donors increased the activity of PTP-PEST. A cGMP analog mimicked the effect of NO, whereas a guanyl cyclase inhibitor blocked it, indicating that elevated cGMP is both necessary and sufficient to induce PTP-PEST activity. Overexpression of wild-type PTP-PEST induced antimotogenesis, whereas expression of dominant negative PTP-PEST blocked the antimotogenic effect of NO, indicating that increased PTP-PEST activity is both sufficient and necessary to explain the effect of NO. Overexpression of PTP-PEST mimicked NO-induced dephosphorylation of adapter protein p130cas, whereas dominant negative PTP-PEST blocked the effect of NO, indicating that upregulation of PTP-PEST is both necessary and sufficient to explain NO-induced p130cas dephosphorylation. Expression of a substrate domain-deleted p130cas decreased motogenesis, whereas overexpression of wild-type p130cas blocked the antimotogenic effect of NO, indicating the functional importance of p130cas dephosphorylation. NO induced dissociation of the Cas-Crk complex, an effect that was mimicked by overexpression of PTP-PEST and opposed by expression of dominant negative PTP-PEST. Our results indicate that NO decreases aortic smooth muscle cell motility via a cGMP-mediated mechanism, involving upregulation of PTP-PEST, in turn inducing dephosphorylation of p130cas, and likely involving Cas-Crk dissociation as a downstream event.
authors.affiliation: Department of Physiology and Vascular Biology Center, University of Tennesee, 894 Union Avenue, Memphis, TN 38163, USA.
authors.forename: Yi
authors.initials: Y
authors.lastname: Lin
authors.forename: Alice Corina
authors.initials: AC
authors.lastname: Ceacareanu
authors.forename: Aviv
authors.initials: A
authors.lastname: Hassid
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001013:Aorta, Thoracic / Q000166:cytology; D002465:Cell Movement / Q000502:physiology*; D002478:Cells, Cultured; D050719:Crk-Associated Substrate Protein; D006152:Cyclic GMP / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D003598:Cytoskeletal Proteins / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005260:Female; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; D015971:Gene Expression Regulation, Enzymologic; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D009131:Muscle, Smooth, Vascular / Q000166:cytology* / Q000201:enzymology; D016296:Mutagenesis; D009569:Nitric Oxide / Q000378:metabolism*; D020030:Nitric Oxide Donors / Q000494:pharmacology; D051419:Paxillin; D010396:Penicillamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D010750:Phosphoproteins / Q000378:metabolism*; D019000:Phosphotyrosine / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011233:Precipitin Tests; D017434:Protein Structure, Tertiary; D054594:Protein Tyrosine Phosphatase, Non-Receptor Type 12; D017027:Protein Tyrosine Phosphatases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011506:Proteins; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D050737:Proto-Oncogene Proteins c-crk; D051381:Rats; D017207:Rats, Sprague-Dawley; D050717:Retinoblastoma-Like Protein p130; D013873:Thionucleotides / Q000494:pharmacology; D014226:Triazenes / Q000494:pharmacology
chemical_list: C105351:1-hydroxy-2-oxo-3,3-bis(2-aminoethyl)-1-triazene; C493843:Bcar1 protein, rat; C493872:Crk protein, rat; D050719:Crk-Associated Substrate Protein; D003598:Cytoskeletal Proteins; D020030:Nitric Oxide Donors; D051419:Paxillin; D010750:Phosphoproteins; D010975:Platelet Aggregation Inhibitors; D011506:Proteins; D011518:Proto-Oncogene Proteins; D050737:Proto-Oncogene Proteins c-crk; C496063:Pxn protein, rat; D050717:Retinoblastoma-Like Protein p130; C110881:S-nitro-N-acetylpenicillamine; D013873:Thionucleotides; D014226:Triazenes; D019000:Phosphotyrosine; D009569:Nitric Oxide; C055656:8-((4-chlorophenyl)thio)cyclic-3',5'-GMP; D011505:Protein-Tyrosine Kinases; D051417:Focal Adhesion Kinase 1; D051416:Focal Adhesion Protein-Tyrosine Kinases; C496052:Ptk2 protein, rat; D054594:Protein Tyrosine Phosphatase, Non-Receptor Type 12; D017027:Protein Tyrosine Phosphatases; C516740:Ptpn12 protein, rat; D006162:Guanylate Cyclase; D010396:Penicillamine; D006152:Cyclic GMP